Sanofi Ends Amlitelimab in Atopic Dermatitis

Company Sanofi Event Type Clinical Program Discontinuation (Phase 3) Modality Non-T-Cell-Depleting Monoclonal Antibody (Anti-OX40L) Asset Amlitelimab Target OX40 Ligand (OX40L) Disease Area Moderate-to-Severe Atopic Dermatitis Summary Sanofi discontinued development of amlitelimab in moderate-to-severe atopic dermatitis and will not seek global approval after concluding that the…